ArticleMycopathologia2019
Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China.
Article in Mycopathologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.Journal of clinical immunology · 2024Pooled it
- Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Talaromyces marneffei infection of central nervous system in an immunocompetent child in a nonendemic area: a case report and literature review.BMC pediatrics · 2026Review
- Timing of Antifungal Treatment and Prognostic Factors in Talaromyces marneffei Infection: A Retrospective Analysis of HIV-Positive Cases.Mycopathologia · 2026Article
- Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity.Frontiers in immunology · 2026Observational
- The role of mNGS in the diagnosis of talaromycosis and case series.BMC infectious diseases · 2025Article
- Human inborn errors of immunity underlyingFrontiers in immunology · 2025Article
- Integrating sequencing methods with machine learning for antimicrobial susceptibility testing in pediatric infections: current advances and future insights.Frontiers in microbiology · 2025Review
- Talaromycosis from Wuhan: two-case report and literature review.Frontiers in cellular and infection microbiology · 2024Review
- UnusualFrontiers in immunology · 2023Review
- Talaromyces marneffei Infections in 8 Chinese Children with Inborn Errors of Immunity.Mycopathologia · 2022Article
- Respiratory infections in X-linked hyper-IgM syndrome with CD40LG mutation: a case series of seven children in China.BMC pediatrics · 2022Article
- Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.Mycopathologia · 2022Review
- Talaromyces marneffei infection associated with bronchiolitis obliterans in an HIV-negative child: a case report.BMC infectious diseases · 2022Article
- Case report: Hemophagocytic lymphohistiocytosis in a child with primary immunodeficiency infected withFrontiers in immunology · 2022Article
- Peripheral immune profile of children with Talaromyces marneffei infections: a retrospective analysis of 21 cases.BMC infectious diseases · 2021Article
- Case Report:Frontiers in immunology · 2021Article
- Disseminated Talaromyces marneffei infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report.BMC infectious diseases · 2020Article
- Sixty Years from Segretain's Description: What Have We Learned and Should Learn About the Basic Mycology of Talaromyces marneffei?Mycopathologia · 2019Article
- Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.Mycopathologia · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Knowledge about the clinical and laboratory characteristics and prognosis of Talaromyces marneffei infection in children is limited. A retrospective study was conducted on pediatric patients with disseminated T. marneffei infection in a clinical setting. Extracted data included demographic information (age and sex), clinical features, laboratory findings, treatment, and prognosis. Eleven HIV-negative children were enrolled. The male/female ratio was 8:3. The median age of onset was 17.5 months (3.5-84 months). The mortality rate in these children was 36.36% (4/11). Seven children had underlying diseases. All of the children had multiple immunoglobulin abnormalities and immune cell decline. Ten children received voriconazole treatment, and most of the children (7/10) had a complete response to therapy at primary and long-term follow-up assessment; only three children died of talaromycosis. One patient recovered from talaromycosis but died of leukemia. The child who received itraconazole treatment also showed clinical improvement. No adverse events associated with antifungal therapies were recorded during and after the treatment. Talaromycosis is an indicator disease for undiagnosed severe immunodeficiencies in children. Awareness of mycoses in children by pediatricians may prompt diagnosis and timely treatment. Voriconazole is an effective, well-tolerated therapeutic option for disseminated T. marneffei infection in non-HIV-infected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.